 | | Vol. 4.45 – 27 November, 2020 |
| |
|
|
| The authors tested the therapeutic efficacy and mechanism of action of a new class of dual G9a histone‐methyltransferase and DNA‐methyltransferase 1 inhibitors.
[Hepatology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers demonstrated that overexpression of Linc‐Pint inhibited the expression of lipogenesis related genes, such as FASN and ACLYM. They also observed that Linc‐Pint significantly inhibits Hepatitis C virus replication.
[Hepatology] |
|
|
|
| The authors showed that Fibroblast Growth Factor-15/19 (FGF15/19) and FGF15/19-activated Small Heterodimer Partner (SHP/NR0B2) had a role in transcriptional repression of lipogenesis.
[Nature Communications] |
|
|
|
| In mouse models of human leukemia, prostate cancer and hepatitis B-induced hepatocellular carcinoma, repeated infusions of polymer nanocarriers induced sufficient host T cells expressing tumor-specific chimeric antigen receptors or virus-specific T cell receptors to cause disease regression at levels similar to bolus infusions of ex vivo engineered lymphocytes.
[Nature Communications] |
|
|
|
| PIDDosome deficiency reduced tumor number and burden, despite the inability to activate p53 in polyploid cells. Liver tumors arose primarily from cells with low ploidy, indicating an intrinsic pro‐tumorigenic effect of PIDDosome‐mediated ploidy restriction.
[EMBO Reports] |
|
|
|
| Ablation of REGγ increased the stability of protein phosphatase 2 catalytic subunit in vitro and in vivo, which dephosphorylated AKT1 substrate 1 and stabilized the interaction between PRAS40 and Raptor to inactive mTORC1-mediated hyper-glycolytic metabolism.
[Oncogene] |
|
|
|
| Human hepatocellular carcinoma cell lines were used to evaluate the colony formation, cell proliferation, migration, invasion, cell cycle and apoptosis after transfection of lentiviral short-hairpin RNAs targeting MYLK-AS1 or MYLK-AS1 vectors.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
| In in vitro assays, NCTC1469 cells subjected to hypoxia/reoxygenation were transduced with siRNA/activator of SIRT1 or miR-182 agomir to confirm the effect of SIRT1 on NCTC1469 cell behaviors as well as the regulation of miR-182 and XBP1/NLRP3 signaling pathway.
[Molecular Therapy-Nucleic Acids] |
|
|
|
| By controlling the degree of substitution and polymer concentration, a gelatin methacryloyl (GelMA) bioink was designed to encapsulate hepatoma cells, as GelMA gel possesses the desired low mechanical stiffness matching that of human liver tissue.
[Scientific Reports] |
|
|
|
| Overexpression of monocyte chemotactic protein-1-induced protein 1 (MCPIP1) decreased hepatitis B virus (HBV) RNA, whereas ablating MCPIP1 in vitro enhanced HBV production. The domains responsible for RNase activity or oligomerization, were required for MCPIP1-mediated viral RNA reduction.
[Scientific Reports] |
|
|
|
|
| The authors discuss the transformative experimental strategies that are being leveraged to dissect the key cellular and molecular mechanisms that regulate fibrosis, and the translational approaches that are enabling the emergence of precision medicine-based therapies for patients with fibrosis.
[Nature] |
|
|
|
| To support their functions in health and disease, hepatic stellate cells (HSCs) engage pathways regulating carbohydrate, mitochondrial, lipid, and retinoid homeostasis. In chronic liver injury, HSCs drive hepatic fibrosis and are implicated in inflammation and cancer.
[Cell Metabolism] |
|
|
|
| The authors summarize current methodologies for organoid/spheroid formation and a potential for 3D hepatic cell cultures as novel in vitro models of cholangiopathies.
[Hepatology] |
|
|
|
| Investigators summarize and highlight the role of the cells in liver cancer and propose strategies to therapeutically target them. They also discuss current immunotherapeutic strategies in hepatocellular carcinoma (HCC) and outline recent advances in our understanding of how the therapeutic potential of these agents might be enhanced.
[Cellular & Molecular Immunology] |
|
|
|
|
| Exelixis, Inc. announced that Takeda Pharmaceutical Company Ltd., its partner responsible for the clinical development and commercialization of CABOMETYX® in Japan, received approval from the Japanese Ministry of Health, Labor and Welfare to manufacture and market CABOMETYX as a treatment for patients with unresectable hepatocellular carcinoma that has progressed after prior systemic therapy.
[Exelixis, Inc.] |
|
|
|
| Median Technologies announced results of a preliminary retrospective study on the evaluation of the severity of hepatic fibrosis in NASH patients using a new imaging biomarker extracted from MRI/MRE images.
[Median Technologies] |
|
|
|
|
| April 11 – April 13, 2021
San Diego, California, United States |
|
|
|
|
|
| | NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| | Karolinska Institutet – Stockholm, Sweden |
|
|
|
| | Stanford University – Stanford, California, United States |
|
|
|
| | University of Michigan – Ann Arbor, Michigan, United States |
|
|
|
| | IRCCS Candiolo Cancer Institute – Candiolo, Italy |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
